Status:
WITHDRAWN
PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care
Lead Sponsor:
University of Florida
Conditions:
Blood Coagulation Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Warfarin (also called Coumadin®) is an anticoagulant drug (blood thinner) given to patients to help prevent blood clots from forming or to help prevent the growth of an existing blood clot. The purpos...
Detailed Description
Warfarin is the mainstay of therapy in preventing venous thromboembolism (VTE), pulmonary embolism (PE), and subsequent morbidity and mortality. Despite its proven efficacy in reducing the advent of c...
Eligibility Criteria
Inclusion
- Newly initiating warfarin
Exclusion
- Previous use of warfarin
- Cancer
- Hepatic Disease
- History of alcoholism
- Diarrheal illness
- Febrile Illness
- Blood dyscrasias
- Pregnancy
- Medical plan to hold warfarin administration before stable dose is achieved (ie. for surgical intervention)
- Dementia
- Active bleed
- Aneurysm
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00377143
Start Date
July 1 2006
Last Update
February 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shands at the University of Florida
Gainesville, Florida, United States, 32610